A Phase 3 interventional study of Proton Therapy and Photon Therapy in Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v7 and Unresectable Hepatocellular Carcinoma, sponsored by NRG Oncology. Active, not recruiting at 27 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by NRG Oncology · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 926 studies in Carcinoma, Hepatocellular with a site in United States — 160 open to participants now, 245 under way, 17 of them phase 3. Carcinoma, Hepatocellular · United States.
Among the 926 studies in Carcinoma, Hepatocellular with a site in United States, this one is the 169th largest by enrollment of the 775 interventional ones that give a count, is one of 49 that started in 2018, is one of 61 in phase 3, reaches primary completion later than 41 of the 244 other live ones, and was the 502nd registered.
3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.
Browse Carcinoma, Hepatocellular studies →160 of the 926 studies in Carcinoma, Hepatocellular with a site in United States are open now. Recruiting first, the newest first:
University of Arizona · Sites in United States
Ages 18–99
Abramson Cancer Center at Penn Medicine · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+
Varian, a Siemens Healthineers Company · Sites in United States
Ages 21+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
926 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 336 · Phase 2 376 · Phase 3 66 · Phase 4 14
First in 1977; this study’s year is marked. 49 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 116 is above the median of 53 across 2,623 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 36 across the 775 interventional studies, 132 across the 121 observational. Of the 602 that completed or were terminated, 262 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
318 of 926 have an industry lead sponsor. The 10 most frequent:
NRG Oncology is the lead sponsor of 72 studies on the registry; 24 are open to participants now.
NRG Oncology has 2 studies filed under Carcinoma, Hepatocellular — fewer than ten, so there is no comparison to draw.
83 of the studies in Carcinoma, Hepatocellular with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03654053Phase 3VA Office of Research and DevelopmentMulti-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis | 2026-12-31 |
| NCT06109272Phase 3AbbVieA Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) | 2027-01 |
| NCT05822752AbbVieStudy to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) | 2026-11 |
| NCT01918683Abramson Cancer Center at Penn MedicineTACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients | 2026-12 |
| NCT04410302University of California, DavisPatient-Derived Xenografts to Reduce Cancer Health Disparities | 2026-12 |
Add all 83 to your calendar (.ics) → With an account.
Among the 926 studies in Carcinoma, Hepatocellular with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This phase III trial studies how well radiation therapy with protons works compared with photons in treating patients with liver cancer. Radiation therapy, such as photon therapy, uses high energy x-rays to send the radiation inside the body to the tumor while proton therapy uses a beam of proton particles. Proton therapy can stop shortly after penetrating through the tumor and may cause less damage to the surrounding healthy organs and result in better survival in patients with liver cancer.
PRIMARY OBJECTIVE:
I. To determine if overall survival (OS) is different for hepatocellular carcinoma patients treated with protons compared to photons.
SECONDARY OBJECTIVES:
I. To determine the difference in progression-free-survival (PFS) in patients with hepatocellular carcinoma (HCC) treated with protons compared to patients with HCC treated with photons.
II. To determine the difference in local progression (LP) in patients with HCC treated with protons compared to patients with HCC treated with photons.
III. To determine differences in toxicity in patients with HCC treated with protons versus photons.
IV. To determine differences in fatigue, as measured by Patient-Reported Outcomes Measurement Information System (PROMIS) fatigue in patients with HCC treated with protons, versus photons; as well as quality-adjusted survival, if the primary endpoint is met.
V. To determine if there are correlations between the baseline values of hepatocyte growth factor (HGF) and outcomes (OS/PFS/fatigue).
EXPLORATORY OBJECTIVES:
I. To determine differences in overall quality of life, measured by Functional Assessment of Cancer Therapy-Hepatobiliary Cancer (FACT-Hep) in patients with HCC treated with protons.
II. Biospecimen collection for future correlative science projects.
OUTLINE: Patients are randomized to 1 of 2 arms, photon or proton therapy (see Arms and Interventions).
Patients undergo computed tomography (CT) scan, magnetic resonance imaging (MRI) and blood sample collection throughout the study.
After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 3 years, and then yearly thereafter.
The criteria were revised on the registry on Nov 3, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Appropriate stage for study entry based on the following diagnostic workup:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Proton therapy delivered in 5 fractions over 15 days or 15 fractions over 24 days, determined by the treating physician.
Radiation: Proton Therapy
Photon therapy delivered in 5 fractions over 15 days or 15 fractions over 24 days, determined by the treating physician.
Radiation: Photon Therapy
Fractions
Also known as: Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
Fractions
Also known as: Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
Percentage of Participants Alive (Overall Survival)
Survival rates are estimated using the Kaplan-Meier method, censoring participants alive at last known follow-up.
Time frame: From randomization to death or last follow-up. Median follow-up time for all patients at time of analysis was 20.4 months. One- and two-year estimates are reported.
Percentage of Participants Alive Without Progression (Progression-free Survival)
Progression is defined as local, regional, or distant progression. Progression-free survival rates are estimated using the Kaplan-Meier method, censoring participants alive without progression at time of last follow-up.
Time frame: From randomization to progression, death, or last follow-up, whichever occurs first. Median follow-up time for all patients at time of analysis was 20.4 months. One- and two-year estimates are reported.
Percentage of Participants With Local Progression
Local progression rates are estimated using the cumulative incidence method in which death is treated as competing risk and participants alive without local failure are censored at last known follow-up.
Time frame: From randomization to local progression, death, or last follow-up, whichever occurs first. Median follow-up time for all patients at time of analysis was 20.4 months. One- and two-year estimates are reported.
Percentage of Participants With Grade 3+ Treatment-Related Adverse Events
Common Terminology Criteria for Adverse Events (version 5.0) grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. Adverse events reported as possibly, probably, or definitely related to treatment are considered to be treatment-related adverse events.
Time frame: From randomization to death or last follow-up. Median follow-up time for all patients at time of analysis was 20.4 months.
Change From Baseline to One Month in the Patient Reported Outcomes Measurement Information System - Fatigue Short Form version1.0 8a [PROMIS Fatigue Score]
The PROMIS Fatigue Short Form v1.0 8a contains 8 items that assess self-reported fatigue symptoms over the past 7 days. Item responses are summed to obtain a raw score ranging from 8 to 40, which is then converted to a standardized T-score (mean = 50, standard deviation = 10). Higher T-scores indicate greater fatigue. Change from baseline is calculated as the post-baseline T-score minus the baseline T-score, with positive change scores indicating increased fatigue and negative change scores indicating decreased fatigue.
Time frame: Baseline and one month
Quality-adjusted LIfe Years
Was to be calculated using the EuroQol 5-Dimension Three Level Questionnaire (EQ-5D-3L).
Time frame: Baseline up to 12 months
Percentage of Participants Alive (Overall Survival) by Plasma Hepatocyte Growth Factor (HGF) Level
Survival rates are estimated using the Kaplan-Meier method, censoring participants alive at last known follow-up. HGF will be dichotomized at 2311 pg/mL.
Time frame: From randomization to death or last follow-up. One- and two-year estimates will be reported.
Percentage of Participants Alive Without Progression (Progression-free Survival) by HGF Level
Progression is defined as local, regional, or distant progression. Progression-free survival rates are estimated using the Kaplan-Meier method, censoring participants alive without progression at time of last follow-up. HGF will be dichotomized at 2311 pg/mL.
Time frame: From randomization to progression, death, or last follow-up, whichever occurs first. One- and two-year estimates will be reported.
Change From Baseline to One Month in PROMIS Fatigue Score by HGF Level
The PROMIS Fatigue Short Form v1.0 8a contains 8 items that assess self-reported fatigue symptoms over the past 7 days. Item responses are summed to obtain a raw score ranging from 8 to 40, which is then converted to a standardized T-score (mean = 50, standard deviation = 10). Higher T-scores indicate greater fatigue. Change from baseline is calculated as the post-baseline T-score minus the baseline T-score, with positive change scores indicating increased fatigue and negative change scores indicating decreased fatigue. HGF will be dichotomized at 2311 pg/mL.
Time frame: Baseline and one month
Overall Quality of Life by Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) Version 4
Differences between treatment arms in the overall score, the four domains (physical, social, emotional, and functional well-being), and the additional concerns subscale will also be analyzed.
Time frame: Baseline up to 12 months
Title: Percentage of Participants Alive (Overall Survival) by Sex
NIH-required analysis. Survival rates are estimated using the Kaplan-Meier method, censoring participants alive at time of analysis.
Time frame: From randomization to death or last follow-up. Median follow-up for all patients at time of analysis was 20.4 months. Two-year estimates are reported.
Percentage of Participants Alive (Overall Survival) by Race
NIH-required analysis. Survival rates are estimated using the Kaplan-Meier method, censoring participants alive at time of analysis.
Time frame: From randomization to death or last follow-up. Median follow-up time for all patients at time of analysis was 20.4 months. Two-year estimates are reported.
Percentage of Participants Alive (Overall Survival) by Ethnicity
NIH-required analysis. Survival rates are estimated using the Kaplan-Meier method, censoring participants alive at time of analysis.
Time frame: From randomization to death or last follow-up. Median follow-up time for all patients at time of analysis was 20.4 months. Two-year estimates are reported.
| Milestone | Proton Therapy (Arm 1) | Photon Therapy (Arm 2) |
|---|---|---|
| Started | 58 | 58 |
| Primary analysis population | 57 | 58 |
| Safety population | 53 | 55 |
| Completed | 57 | 58 |
| Not completed | 1 | 0 |
Survival rates are estimated using the Kaplan-Meier method, censoring participants alive at last known follow-up.
| Percentage of participants | Proton Therapy (Arm 1) | Photon Therapy (Arm 2) |
|---|---|---|
| One year | 77.0 (66.9 to 87.1) | 90.2 (83.3 to 97.1) |
| Two years | 56.2 (43.9 to 68.4) | 69.3 (57.3 to 81.2) |
Progression is defined as local, regional, or distant progression. Progression-free survival rates are estimated using the Kaplan-Meier method, censoring participants alive without progression at time of last follow-up.
| Percentage of participants | Proton Therapy (Arm 1) | Photon Therapy (Arm 2) |
|---|---|---|
| One year | 55.5 (41.4 to 69.6) | 50.0 (35.6 to 64.4) |
| Two years | 31.6 (17.8 to 45.4) | 30.4 (15.9 to 44.8) |
Local progression rates are estimated using the cumulative incidence method in which death is treated as competing risk and participants alive without local failure are censored at last known follow-up.
| Percentage of participants | Proton Therapy (Arm 1) | Photon Therapy (Arm 2) |
|---|---|---|
| One year | 10.5 (3.8 to 21.2) | 15.1 (6.5 to 26.9) |
| Two years | 19.8 (9.6 to 32.7) | 22.3 (11.3 to 35.5) |
Common Terminology Criteria for Adverse Events (version 5.0) grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. Adverse events reported as possibly, probably, or definitely related to treatment are considered to be treatment-related adverse events.
| Percentage of participants | Proton Therapy (Arm 1) | Photon Therapy (Arm 2) |
|---|---|---|
| Percentage of Participants With Grade 3+ Treatment-Related Adverse Events | 11.3 (4.3 to 23.0) | 23.6 (13.2 to 37.0) |
The PROMIS Fatigue Short Form v1.0 8a contains 8 items that assess self-reported fatigue symptoms over the past 7 days. Item responses are summed to obtain a raw score ranging from 8 to 40, which is then converted to a standardized T-score (mean = 50, standard deviation = 10). Higher T-scores indicate greater fatigue. Change from baseline is calculated as the post-baseline T-score minus the baseline T-score, with positive change scores indicating increased fatigue and negative change scores indicating decreased fatigue.
Results for this outcome have not been posted.
Was to be calculated using the EuroQol 5-Dimension Three Level Questionnaire (EQ-5D-3L).
No measurements were reported for this outcome.
Survival rates are estimated using the Kaplan-Meier method, censoring participants alive at last known follow-up. HGF will be dichotomized at 2311 pg/mL.
Results for this outcome have not been posted.
Differences between treatment arms in the overall score, the four domains (physical, social, emotional, and functional well-being), and the additional concerns subscale will also be analyzed.
Results for this outcome have not been posted.
NIH-required analysis. Survival rates are estimated using the Kaplan-Meier method, censoring participants alive at time of analysis.
| Percentage of participants | Proton Therapy (Arm 1) | Photon Therapy (Arm 2) |
|---|---|---|
| Female | 66.1 (43.2 to 89.0) | 56.3 (29.1 to 83.4) |
| Male | 52.8 (38.5 to 67.1) | 73.1 (60.1 to 86.1) |
NIH-required analysis. Survival rates are estimated using the Kaplan-Meier method, censoring participants alive at time of analysis.
| Percentage of participants | Proton Therapy (Arm 1) | Photon Therapy (Arm 2) |
|---|---|---|
| Asian | NA (NA to NA) | 100 (NA to NA) |
| Black or African American | 100 (NA to NA) | 50 (8.9 to 91.1) |
| White | 53.2 (40.5 to 65.9) | 73.7 (61.0 to 86.3) |
| More than one race | NA (NA to NA) | — |
| Unknown or Not Reported | 100 (NA to NA) | 41.7 (0.0 to 91.7) |
NIH-required analysis. Survival rates are estimated using the Kaplan-Meier method, censoring participants alive at time of analysis.
| Percentage of participants | Proton Therapy (Arm 1) | Photon Therapy (Arm 2) |
|---|---|---|
| Hispanic or Latino | 71.4 (43.3 to 99.5) | 87.5 (68.3 to 100.0) |
| Not Hispanic or Latino | 57.5 (43.6 to 71.4) | 59.3 (44.0 to 74.6) |
| Unknown or Not Reported | 0 (NA to NA) | 100 (NA to NA) |
Progression is defined as local, regional, or distant progression. Progression-free survival rates are estimated using the Kaplan-Meier method, censoring participants alive without progression at time of last follow-up. HGF will be dichotomized at 2311 pg/mL.
Results for this outcome have not been posted.
The PROMIS Fatigue Short Form v1.0 8a contains 8 items that assess self-reported fatigue symptoms over the past 7 days. Item responses are summed to obtain a raw score ranging from 8 to 40, which is then converted to a standardized T-score (mean = 50, standard deviation = 10). Higher T-scores indicate greater fatigue. Change from baseline is calculated as the post-baseline T-score minus the baseline T-score, with positive change scores indicating increased fatigue and negative change scores indicating decreased fatigue. HGF will be dichotomized at 2311 pg/mL.
Results for this outcome have not been posted.
Collected over From randomization to death or last follow-up. Median follow-up at time of analysis was 20.4 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Proton Therapy (Arm 1) | 30/57 (52.6%) | 1/53 (1.9%) | 53/53 (100%) |
| Photon Therapy (Arm 2) | 24/58 (41.4%) | 5/55 (9.1%) | 55/55 (100%) |
| Event | Proton Therapy (Arm 1) | Photon Therapy (Arm 2) |
|---|---|---|
| Hepatic failureHepatobiliary disorders | 0/53 | 2/55 |
| Colonic obstructionGastrointestinal disorders | 1/53 | 0/55 |
| Surgical and medical procedures - Other, specifySurgical and medical procedures | 1/53 | 0/55 |
| AnemiaBlood and lymphatic system disorders | 0/53 | 1/55 |
| Upper gastrointestinal hemorrhageGastrointestinal disorders | 0/53 | 1/55 |
| Infections and infestations - Other, specifyInfections and infestations | 0/53 | 1/55 |
| Blood bilirubin increasedInvestigations | 0/53 | 1/55 |
| HyperglycemiaMetabolism and nutrition disorders | 0/53 | 1/55 |
| SyncopeNervous system disorders | 0/53 | 1/55 |
| ConfusionPsychiatric disorders | 0/53 | 1/55 |
| Event | Proton Therapy (Arm 1) | Photon Therapy (Arm 2) |
|---|---|---|
| FatigueGeneral disorders and administration site conditions | 43/53 | 40/55 |
| Platelet count decreasedInvestigations | 29/53 | 32/55 |
| Lymphocyte count decreasedInvestigations | 20/53 | 28/55 |
| AnemiaBlood and lymphatic system disorders | 26/53 | 23/55 |
| NauseaGastrointestinal disorders | 20/53 | 26/55 |
| ConstipationGastrointestinal disorders | 24/53 | 17/55 |
| Abdominal painGastrointestinal disorders | 17/53 | 24/55 |
| Alkaline phosphatase increasedInvestigations | 20/53 | 22/55 |
| DiarrheaGastrointestinal disorders | 14/53 | 21/55 |
| White blood cell decreasedInvestigations | 11/53 | 21/55 |
| Age, Continuous(years) | Proton Therapy (Arm 1) | Photon Therapy (Arm 2) | Total |
|---|---|---|---|
| Median | 73 (66 to 79) | 71 (65 to 79) | 72 (65 to 79) |
| Sex: Female, Male(Participants) | Proton Therapy (Arm 1) | Photon Therapy (Arm 2) | Total |
|---|---|---|---|
| Female | 14 | 10 | 24 |
| Male | 43 | 48 | 91 |
| Race (NIH/OMB)(Participants) | Proton Therapy (Arm 1) | Photon Therapy (Arm 2) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 4 | 5 |
| White | 50 | 47 | 97 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 3 | 6 | 9 |
| Ethnicity (NIH/OMB)(Participants) | Proton Therapy (Arm 1) | Photon Therapy (Arm 2) | Total |
|---|---|---|---|
| Hispanic or Latino | 8 | 13 | 21 |
| Not Hispanic or Latino | 45 | 39 | 84 |
| Unknown or Not Reported | 4 | 6 | 10 |
| Zubrod Performance Status(Participants) | Proton Therapy (Arm 1) | Photon Therapy (Arm 2) | Total |
|---|---|---|---|
| 0 | 26 | 24 | 50 |
| 1 | 31 | 34 | 65 |
| Child Pugh Score(Participants) | Proton Therapy (Arm 1) | Photon Therapy (Arm 2) | Total |
|---|---|---|---|
| A5 | 39 | 41 | 80 |
| A6 | 14 | 13 | 27 |
| B7 | 4 | 4 | 8 |
| Alpha-fetoprotein (AFP)(mg/mL) | Proton Therapy (Arm 1) | Photon Therapy (Arm 2) | Total |
|---|---|---|---|
| Median | 6.6 (3.6 to 88.7) | 12.1 (3.4 to 179.4) | 9.5 (3.6 to 169.7) |
| Prior treatment for this cancer(Participants) | Proton Therapy (Arm 1) | Photon Therapy (Arm 2) | Total |
|---|---|---|---|
| No | 39 | 47 | 86 |
| Yes | 18 | 11 | 29 |
8 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Data sharing details ↗ · grants.nih.gov
Ran from Jan 2018 to primary completion in Jan 2026, 95 months.
Results were first posted in Nov 2026, 9 months after primary completion.
Of 86 non-industry phase 3 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 70 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 109. This study's 95 months is above that.
Counting every sponsor, half of 139 studies reached it within 56 months; a quarter within 43 and three quarters within 83.
Completion moved once since we started tracking on Sep 25, 2026: Feb 2027 → Jan 2031, on Nov 3, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
NRG Oncology